Allegheny Health Network | Association Partnerships

Allegheny Health Network is proud to offer a comprehensive program dedicated to providing the highest quality care for patients with esophageal and gastric cancer.

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

In an interview with Targeted Oncology, Ariel Lopez-Chavez, MD, discussed recent developments in the small cell lung cancer space.

Ariel Lopez-Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Ariel Lopez-Chavez, MD, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer.

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

Clinicians at the AHN Cancer Institute lead the way with CAR T-cell therapy and other innovative treatments for hematological cancers.

AHN Cancer Institute’s Centers of Excellence unite teams of experts to provide patients with high-quality, collaborative care in a supportive environment.

The cancer navigation program at Allegheny Health Network supports all cancer patients from diagnosis to treatment and beyond.

The fight against pancreatic cancer is a complex one, marked by challenging outcomes and a constant search for effective treatments. But at the Allegheny Health Network Cancer Institute, a team of specialists are turning the tide on the disease through early intervention, collaboration, and research.

As part of its Speaking Out series, Patrick Wagner, MD, discusses eligibility and considerations for oncolytic viral therapies.

As part of its Speaking Out video series, Howard D. Edington, MD, explores how oncolytic viruses are revolutionizing personalized cancer therapy, the challenges of interpreting vast genetic data, and the exciting potential of these targeted therapies.

Targeted Oncology spoke with Howard D. Edington, MD, about how experts are addressing the potential of resistance challenges with oncolytic viruses as part of its Speaking Out video series.

Targeted Oncology spoke with Howard D. Edington, MD, about the advancements in engineering oncolytic viruses to be able to target specific cancers and various combination therapies with the novel treatment.

Immune therapy drugs show promise in treating esophageal cancer.

Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.

Ariel Lopez-Chavez, MD, discusses ongoing research in the small cell lung cancer space.

As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer treatment.

For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.

Ariel Lopez-Chavez, MD, discusses the potential of tarlatamab and its use in the frontline setting for the treatment of patients with small cell lung cancer.

David L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.

David L. Bartlett, MD, discusses the benefits of genomic testing for patients with cancer and how the approach to genomic testing has changed over the years.

In an interview with Targeted Oncology, Nasir Chaudry, MD, discussed the evolving landscape of prostate cancer treatment, driven by new research.

In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.

Researchers from Allegheny Health Network, Baylor Scott & White Health, and Johns Hopkins Medicine have found that two newly approved immunotherapies can help to improve two-year survival rates for patients with gastroesophageal cancers.

Lifileucel's FDA approval marks a breakthrough in melanoma treatment, offering hope with promising antitumor activity. While its potential extends to various solid tumors, challenges persist.

Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.

In an interview with Targeted Oncology, Howard D. Edington, MD, discussed Allegheny Health Network’s recently unveiled Melanoma and Skin Cancer Center and its new technology.